Dementia researchers downplay Novo announcement: Let us see some data
Two of the country's leading researchers in dementia and Alzheimer's disease have been critical about the two announcements from Novo Nordisk about a possible breakthrough within Alzheimer's. It is a premature announcement, and Novo Nordisk hasn't presented concete data, they say. "I wouldn't give it too much weight," says consultant and professor Steen Gregers Hasselbach.
The stock market was buzzing late on Tueday night when it was announced that Novo Nordisk had told participants at the J.P Morgan conference in the USA that they had new data which proved with "statistical significance" that diabetes drug Victorza (liraglutid) can delay the onset of dementia.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck and rivals join forces in new research alliance
For abonnenter
